Ameritas Investment Partners’s Bellicum Pharmaceuticals, Inc. BLCM Stock Holding History

Ameritas Investment Partners’s Portfolio BLCM Stock Details BLCM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-433	Closed	-$15K	–	3135
2019 Q1	$15K	Hold	433	–	–	﹤0.01%	2544
2018 Q4	$13K	Hold	433	–	–	﹤0.01%	2573
2018 Q3	$27K	Hold	433	–	–	﹤0.01%	2366
2018 Q2	$32K	Buy	433 +194	+81%	+$15.1K	﹤0.01%	2256
2018 Q1	$16K	Hold	239	–	–	﹤0.01%	2539
2017 Q4	$20K	Hold	239	–	–	﹤0.01%	2442
2017 Q3	$25K	Hold	239	–	–	﹤0.01%	2321
2017 Q2	$28K	Buy	239 +76	+47%	+$9.43K	﹤0.01%	2275
2017 Q1	$20K	Buy	+163	New	+$21.4K	﹤0.01%	2410

Other funds holding BLCM

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Ameritas Investment Partners's BLCM Position: Q2 2019 in Review

Ameritas Investment Partners sold out of Bellicum Pharmaceuticals, Inc. (BLCM) in Q2 2019, closing a stake of 433 shares — an estimated $15K sold.

Ameritas Investment Partners first reported a position in BLCM in Q1 2017 and held it in 9 quarters. The position peaked at $32K in Q2 2018. 79 funds tracked by Wall St. Rank hold BLCM as of Q2 2019.

Ameritas Investment Partners reported no remaining Bellicum Pharmaceuticals, Inc. position as of Q2 2019 after selling out during the quarter.
Ameritas Investment Partners sold 433 Bellicum Pharmaceuticals, Inc. shares in Q2 2019, an estimated $15K.
Ameritas Investment Partners first reported a position in Bellicum Pharmaceuticals, Inc. in Q1 2017 and held it in 9 quarters.
Ameritas Investment Partners's Bellicum Pharmaceuticals, Inc. position peaked at $32K in Q2 2018.
79 funds tracked by Wall St. Rank held Bellicum Pharmaceuticals, Inc. as of Q2 2019.

Based on Ameritas Investment Partners's 13F filing for Q2 2019, filed 14 Aug 2019.